nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—ADRA2A—type 2 diabetes mellitus	0.288	1	CbGaD
Zuclopenthixol—DRD5—Bromocriptine—type 2 diabetes mellitus	0.108	0.249	CbGbCtD
Zuclopenthixol—HTR6—Bromocriptine—type 2 diabetes mellitus	0.0691	0.16	CbGbCtD
Zuclopenthixol—DRD1—Bromocriptine—type 2 diabetes mellitus	0.0549	0.127	CbGbCtD
Zuclopenthixol—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0362	0.0839	CbGbCtD
Zuclopenthixol—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.0362	0.0839	CbGbCtD
Zuclopenthixol—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0347	0.0804	CbGbCtD
Zuclopenthixol—DRD2—Bromocriptine—type 2 diabetes mellitus	0.0334	0.0773	CbGbCtD
Zuclopenthixol—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0175	0.0406	CbGbCtD
Zuclopenthixol—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0162	0.0375	CbGbCtD
Zuclopenthixol—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.0133	0.0308	CbGbCtD
Zuclopenthixol—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.0127	0.0295	CbGbCtD
Zuclopenthixol—HTR2A—arteriole—type 2 diabetes mellitus	0.00311	0.16	CbGeAlD
Zuclopenthixol—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.00198	0.102	CbGeAlD
Zuclopenthixol—DRD1—nerve—type 2 diabetes mellitus	0.00192	0.0992	CbGeAlD
Zuclopenthixol—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.00133	0.0687	CbGeAlD
Zuclopenthixol—HTR2A—hindlimb—type 2 diabetes mellitus	0.00123	0.0636	CbGeAlD
Zuclopenthixol—DRD2—nerve—type 2 diabetes mellitus	0.00113	0.0586	CbGeAlD
Zuclopenthixol—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.00113	0.0583	CbGeAlD
Zuclopenthixol—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.00096	0.0496	CbGeAlD
Zuclopenthixol—HTR2A—artery—type 2 diabetes mellitus	0.000754	0.039	CbGeAlD
Zuclopenthixol—HTR2A—nerve—type 2 diabetes mellitus	0.000748	0.0387	CbGeAlD
Zuclopenthixol—HTR2A—endothelium—type 2 diabetes mellitus	0.000637	0.0329	CbGeAlD
Zuclopenthixol—DRD2—retina—type 2 diabetes mellitus	0.00047	0.0243	CbGeAlD
Zuclopenthixol—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000426	0.022	CbGeAlD
Zuclopenthixol—ADRA1A—cardiovascular system—type 2 diabetes mellitus	0.000406	0.0209	CbGeAlD
Zuclopenthixol—ADRA1A—adipose tissue—type 2 diabetes mellitus	0.000358	0.0185	CbGeAlD
Zuclopenthixol—HTR2A—retina—type 2 diabetes mellitus	0.00031	0.016	CbGeAlD
Zuclopenthixol—ADRA2A—pancreas—type 2 diabetes mellitus	0.0003	0.0155	CbGeAlD
Zuclopenthixol—ADRA2A—cortex of kidney—type 2 diabetes mellitus	0.000294	0.0152	CbGeAlD
Zuclopenthixol—HRH1—adipose tissue—type 2 diabetes mellitus	0.000277	0.0143	CbGeAlD
Zuclopenthixol—ADRA2A—adipose tissue—type 2 diabetes mellitus	0.000272	0.014	CbGeAlD
Zuclopenthixol—HTR2A—cardiovascular system—type 2 diabetes mellitus	0.000262	0.0135	CbGeAlD
Zuclopenthixol—HTR2A—kidney—type 2 diabetes mellitus	0.000257	0.0133	CbGeAlD
Zuclopenthixol—ADRA1A—liver—type 2 diabetes mellitus	0.000251	0.013	CbGeAlD
Zuclopenthixol—CYP2D6—kidney—type 2 diabetes mellitus	0.000234	0.0121	CbGeAlD
Zuclopenthixol—Fluphenazine—CALM1—type 2 diabetes mellitus	0.000212	0.0485	CrCbGaD
Zuclopenthixol—Propericiazine—ADRA2A—type 2 diabetes mellitus	0.00018	0.0411	CrCbGaD
Zuclopenthixol—Trifluoperazine—CALM1—type 2 diabetes mellitus	0.00017	0.0388	CrCbGaD
Zuclopenthixol—Perphenazine—CALM1—type 2 diabetes mellitus	0.000168	0.0384	CrCbGaD
Zuclopenthixol—HTR2A—liver—type 2 diabetes mellitus	0.000162	0.00838	CbGeAlD
Zuclopenthixol—CYP2D6—liver—type 2 diabetes mellitus	0.000148	0.00763	CbGeAlD
Zuclopenthixol—Chlorpromazine—CALM1—type 2 diabetes mellitus	0.000133	0.0304	CrCbGaD
Zuclopenthixol—Nefazodone—ADRA2A—type 2 diabetes mellitus	0.000128	0.0293	CrCbGaD
Zuclopenthixol—Trazodone—ADRA2A—type 2 diabetes mellitus	0.000119	0.0271	CrCbGaD
Zuclopenthixol—Nefazodone—HTR2C—type 2 diabetes mellitus	0.000118	0.027	CrCbGaD
Zuclopenthixol—Thiothixene—ADRA2A—type 2 diabetes mellitus	0.000111	0.0254	CrCbGaD
Zuclopenthixol—Trazodone—HTR2C—type 2 diabetes mellitus	0.000109	0.025	CrCbGaD
Zuclopenthixol—Domperidone—CYP1A2—type 2 diabetes mellitus	0.000107	0.0245	CrCbGaD
Zuclopenthixol—Thiothixene—HTR2C—type 2 diabetes mellitus	0.000102	0.0234	CrCbGaD
Zuclopenthixol—Prochlorperazine—HTR2C—type 2 diabetes mellitus	9.79e-05	0.0224	CrCbGaD
Zuclopenthixol—Amoxapine—ADRA2A—type 2 diabetes mellitus	9.78e-05	0.0223	CrCbGaD
Zuclopenthixol—Fluphenazine—ADRA2A—type 2 diabetes mellitus	9.62e-05	0.022	CrCbGaD
Zuclopenthixol—Rash—Glimepiride—type 2 diabetes mellitus	9.58e-05	0.00055	CcSEcCtD
Zuclopenthixol—Dermatitis—Glimepiride—type 2 diabetes mellitus	9.57e-05	0.000549	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	9.57e-05	0.000549	CcSEcCtD
Zuclopenthixol—Rash—Sitagliptin—type 2 diabetes mellitus	9.55e-05	0.000548	CcSEcCtD
Zuclopenthixol—Dermatitis—Sitagliptin—type 2 diabetes mellitus	9.54e-05	0.000548	CcSEcCtD
Zuclopenthixol—Headache—Glimepiride—type 2 diabetes mellitus	9.52e-05	0.000546	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Losartan—type 2 diabetes mellitus	9.51e-05	0.000545	CcSEcCtD
Zuclopenthixol—Headache—Sitagliptin—type 2 diabetes mellitus	9.49e-05	0.000544	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	9.42e-05	0.00054	CcSEcCtD
Zuclopenthixol—Agitation—Losartan—type 2 diabetes mellitus	9.42e-05	0.00054	CcSEcCtD
Zuclopenthixol—Tinnitus—Ramipril—type 2 diabetes mellitus	9.41e-05	0.00054	CcSEcCtD
Zuclopenthixol—Hypertension—Irbesartan—type 2 diabetes mellitus	9.4e-05	0.000539	CcSEcCtD
Zuclopenthixol—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	9.38e-05	0.000538	CcSEcCtD
Zuclopenthixol—Insomnia—Valsartan—type 2 diabetes mellitus	9.35e-05	0.000537	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	9.31e-05	0.000534	CcSEcCtD
Zuclopenthixol—Paraesthesia—Valsartan—type 2 diabetes mellitus	9.28e-05	0.000533	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	9.27e-05	0.000532	CcSEcCtD
Zuclopenthixol—Myalgia—Irbesartan—type 2 diabetes mellitus	9.27e-05	0.000532	CcSEcCtD
Zuclopenthixol—Shock—Metformin—type 2 diabetes mellitus	9.26e-05	0.000531	CcSEcCtD
Zuclopenthixol—Insomnia—Orlistat—type 2 diabetes mellitus	9.24e-05	0.00053	CcSEcCtD
Zuclopenthixol—Malaise—Losartan—type 2 diabetes mellitus	9.24e-05	0.00053	CcSEcCtD
Zuclopenthixol—Anxiety—Irbesartan—type 2 diabetes mellitus	9.24e-05	0.00053	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Glyburide—type 2 diabetes mellitus	9.23e-05	0.00053	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Metformin—type 2 diabetes mellitus	9.23e-05	0.00053	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Metformin—type 2 diabetes mellitus	9.22e-05	0.000529	CcSEcCtD
Zuclopenthixol—Dyspnoea—Valsartan—type 2 diabetes mellitus	9.22e-05	0.000529	CcSEcCtD
Zuclopenthixol—Vertigo—Losartan—type 2 diabetes mellitus	9.2e-05	0.000528	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	9.2e-05	0.000528	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	9.2e-05	0.000528	CcSEcCtD
Zuclopenthixol—Somnolence—Valsartan—type 2 diabetes mellitus	9.19e-05	0.000527	CcSEcCtD
Zuclopenthixol—Syncope—Losartan—type 2 diabetes mellitus	9.19e-05	0.000527	CcSEcCtD
Zuclopenthixol—Paraesthesia—Orlistat—type 2 diabetes mellitus	9.17e-05	0.000526	CcSEcCtD
Zuclopenthixol—Leukopenia—Losartan—type 2 diabetes mellitus	9.17e-05	0.000526	CcSEcCtD
Zuclopenthixol—Discomfort—Irbesartan—type 2 diabetes mellitus	9.16e-05	0.000525	CcSEcCtD
Zuclopenthixol—Skin disorder—Metformin—type 2 diabetes mellitus	9.15e-05	0.000525	CcSEcCtD
Zuclopenthixol—Immune system disorder—Ramipril—type 2 diabetes mellitus	9.12e-05	0.000523	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Metformin—type 2 diabetes mellitus	9.1e-05	0.000522	CcSEcCtD
Zuclopenthixol—Dyspepsia—Valsartan—type 2 diabetes mellitus	9.1e-05	0.000522	CcSEcCtD
Zuclopenthixol—Dizziness—Bromocriptine—type 2 diabetes mellitus	9.07e-05	0.00052	CcSEcCtD
Zuclopenthixol—Dry mouth—Irbesartan—type 2 diabetes mellitus	9.06e-05	0.00052	CcSEcCtD
Zuclopenthixol—Palpitations—Losartan—type 2 diabetes mellitus	9.05e-05	0.000519	CcSEcCtD
Zuclopenthixol—Nausea—Glimepiride—type 2 diabetes mellitus	9.03e-05	0.000518	CcSEcCtD
Zuclopenthixol—Arrhythmia—Ramipril—type 2 diabetes mellitus	9.02e-05	0.000517	CcSEcCtD
Zuclopenthixol—Amoxapine—HTR2C—type 2 diabetes mellitus	9.01e-05	0.0206	CrCbGaD
Zuclopenthixol—Loss of consciousness—Losartan—type 2 diabetes mellitus	9e-05	0.000517	CcSEcCtD
Zuclopenthixol—Nausea—Sitagliptin—type 2 diabetes mellitus	9e-05	0.000516	CcSEcCtD
Zuclopenthixol—Dyspepsia—Orlistat—type 2 diabetes mellitus	8.99e-05	0.000516	CcSEcCtD
Zuclopenthixol—Asthenia—Glyburide—type 2 diabetes mellitus	8.99e-05	0.000516	CcSEcCtD
Zuclopenthixol—Decreased appetite—Valsartan—type 2 diabetes mellitus	8.99e-05	0.000516	CcSEcCtD
Zuclopenthixol—Anorexia—Metformin—type 2 diabetes mellitus	8.97e-05	0.000515	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	8.93e-05	0.000512	CcSEcCtD
Zuclopenthixol—Fatigue—Valsartan—type 2 diabetes mellitus	8.91e-05	0.000511	CcSEcCtD
Zuclopenthixol—Abdominal pain—Gliclazide—type 2 diabetes mellitus	8.9e-05	0.00051	CcSEcCtD
Zuclopenthixol—Body temperature increased—Gliclazide—type 2 diabetes mellitus	8.9e-05	0.00051	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	8.89e-05	0.00051	CcSEcCtD
Zuclopenthixol—Decreased appetite—Orlistat—type 2 diabetes mellitus	8.88e-05	0.00051	CcSEcCtD
Zuclopenthixol—Pruritus—Glyburide—type 2 diabetes mellitus	8.87e-05	0.000509	CcSEcCtD
Zuclopenthixol—Fluphenazine—HTR2C—type 2 diabetes mellitus	8.85e-05	0.0202	CrCbGaD
Zuclopenthixol—Mental disorder—Ramipril—type 2 diabetes mellitus	8.84e-05	0.000507	CcSEcCtD
Zuclopenthixol—Constipation—Valsartan—type 2 diabetes mellitus	8.84e-05	0.000507	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	8.82e-05	0.000506	CcSEcCtD
Zuclopenthixol—Fatigue—Orlistat—type 2 diabetes mellitus	8.81e-05	0.000505	CcSEcCtD
Zuclopenthixol—Hypotension—Metformin—type 2 diabetes mellitus	8.8e-05	0.000505	CcSEcCtD
Zuclopenthixol—Erythema—Ramipril—type 2 diabetes mellitus	8.79e-05	0.000504	CcSEcCtD
Zuclopenthixol—Malnutrition—Ramipril—type 2 diabetes mellitus	8.79e-05	0.000504	CcSEcCtD
Zuclopenthixol—Shock—Irbesartan—type 2 diabetes mellitus	8.74e-05	0.000502	CcSEcCtD
Zuclopenthixol—Pain—Orlistat—type 2 diabetes mellitus	8.74e-05	0.000501	CcSEcCtD
Zuclopenthixol—Myalgia—Losartan—type 2 diabetes mellitus	8.72e-05	0.0005	CcSEcCtD
Zuclopenthixol—Vomiting—Bromocriptine—type 2 diabetes mellitus	8.72e-05	0.0005	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	8.71e-05	0.0005	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	8.7e-05	0.000499	CcSEcCtD
Zuclopenthixol—Anxiety—Losartan—type 2 diabetes mellitus	8.69e-05	0.000499	CcSEcCtD
Zuclopenthixol—Tachycardia—Irbesartan—type 2 diabetes mellitus	8.67e-05	0.000498	CcSEcCtD
Zuclopenthixol—Rash—Bromocriptine—type 2 diabetes mellitus	8.64e-05	0.000496	CcSEcCtD
Zuclopenthixol—Dermatitis—Bromocriptine—type 2 diabetes mellitus	8.64e-05	0.000495	CcSEcCtD
Zuclopenthixol—Skin disorder—Irbesartan—type 2 diabetes mellitus	8.63e-05	0.000495	CcSEcCtD
Zuclopenthixol—Tension—Ramipril—type 2 diabetes mellitus	8.62e-05	0.000495	CcSEcCtD
Zuclopenthixol—Discomfort—Losartan—type 2 diabetes mellitus	8.62e-05	0.000494	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	8.59e-05	0.000493	CcSEcCtD
Zuclopenthixol—Headache—Bromocriptine—type 2 diabetes mellitus	8.59e-05	0.000493	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	8.58e-05	0.000492	CcSEcCtD
Zuclopenthixol—Diarrhoea—Glyburide—type 2 diabetes mellitus	8.57e-05	0.000492	CcSEcCtD
Zuclopenthixol—Nervousness—Ramipril—type 2 diabetes mellitus	8.53e-05	0.00049	CcSEcCtD
Zuclopenthixol—Dry mouth—Losartan—type 2 diabetes mellitus	8.53e-05	0.000489	CcSEcCtD
Zuclopenthixol—Anorexia—Irbesartan—type 2 diabetes mellitus	8.47e-05	0.000486	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	8.45e-05	0.000485	CcSEcCtD
Zuclopenthixol—Paraesthesia—Metformin—type 2 diabetes mellitus	8.45e-05	0.000485	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Orlistat—type 2 diabetes mellitus	8.42e-05	0.000483	CcSEcCtD
Zuclopenthixol—Dyspnoea—Metformin—type 2 diabetes mellitus	8.39e-05	0.000482	CcSEcCtD
Zuclopenthixol—Somnolence—Metformin—type 2 diabetes mellitus	8.37e-05	0.00048	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Losartan—type 2 diabetes mellitus	8.36e-05	0.00048	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	8.35e-05	0.000479	CcSEcCtD
Zuclopenthixol—Hypotension—Irbesartan—type 2 diabetes mellitus	8.3e-05	0.000476	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	8.29e-05	0.000476	CcSEcCtD
Zuclopenthixol—Dyspepsia—Metformin—type 2 diabetes mellitus	8.29e-05	0.000476	CcSEcCtD
Zuclopenthixol—Thioridazine—ADRA2A—type 2 diabetes mellitus	8.29e-05	0.0189	CrCbGaD
Zuclopenthixol—Tremor—Ramipril—type 2 diabetes mellitus	8.23e-05	0.000472	CcSEcCtD
Zuclopenthixol—Shock—Losartan—type 2 diabetes mellitus	8.23e-05	0.000472	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Losartan—type 2 diabetes mellitus	8.2e-05	0.00047	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Losartan—type 2 diabetes mellitus	8.19e-05	0.00047	CcSEcCtD
Zuclopenthixol—Decreased appetite—Metformin—type 2 diabetes mellitus	8.18e-05	0.00047	CcSEcCtD
Zuclopenthixol—Abdominal pain—Valsartan—type 2 diabetes mellitus	8.17e-05	0.000469	CcSEcCtD
Zuclopenthixol—Tachycardia—Losartan—type 2 diabetes mellitus	8.16e-05	0.000468	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	8.15e-05	0.000468	CcSEcCtD
Zuclopenthixol—Nausea—Bromocriptine—type 2 diabetes mellitus	8.14e-05	0.000467	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	8.13e-05	0.000466	CcSEcCtD
Zuclopenthixol—Fatigue—Metformin—type 2 diabetes mellitus	8.12e-05	0.000466	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	8.09e-05	0.000464	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Losartan—type 2 diabetes mellitus	8.08e-05	0.000464	CcSEcCtD
Zuclopenthixol—Abdominal pain—Orlistat—type 2 diabetes mellitus	8.08e-05	0.000463	CcSEcCtD
Zuclopenthixol—Body temperature increased—Orlistat—type 2 diabetes mellitus	8.08e-05	0.000463	CcSEcCtD
Zuclopenthixol—Asthenia—Gliclazide—type 2 diabetes mellitus	8.07e-05	0.000463	CcSEcCtD
Zuclopenthixol—Agitation—Ramipril—type 2 diabetes mellitus	8.07e-05	0.000463	CcSEcCtD
Zuclopenthixol—Chlorprothixene—HTR2C—type 2 diabetes mellitus	8.06e-05	0.0184	CrCbGaD
Zuclopenthixol—Constipation—Metformin—type 2 diabetes mellitus	8.05e-05	0.000462	CcSEcCtD
Zuclopenthixol—Paraesthesia—Irbesartan—type 2 diabetes mellitus	7.98e-05	0.000458	CcSEcCtD
Zuclopenthixol—Anorexia—Losartan—type 2 diabetes mellitus	7.97e-05	0.000457	CcSEcCtD
Zuclopenthixol—Vomiting—Glyburide—type 2 diabetes mellitus	7.97e-05	0.000457	CcSEcCtD
Zuclopenthixol—Pruritus—Gliclazide—type 2 diabetes mellitus	7.96e-05	0.000457	CcSEcCtD
Zuclopenthixol—Malaise—Ramipril—type 2 diabetes mellitus	7.92e-05	0.000455	CcSEcCtD
Zuclopenthixol—Dyspnoea—Irbesartan—type 2 diabetes mellitus	7.92e-05	0.000454	CcSEcCtD
Zuclopenthixol—Rash—Glyburide—type 2 diabetes mellitus	7.9e-05	0.000453	CcSEcCtD
Zuclopenthixol—Somnolence—Irbesartan—type 2 diabetes mellitus	7.9e-05	0.000453	CcSEcCtD
Zuclopenthixol—Dermatitis—Glyburide—type 2 diabetes mellitus	7.89e-05	0.000453	CcSEcCtD
Zuclopenthixol—Vertigo—Ramipril—type 2 diabetes mellitus	7.89e-05	0.000453	CcSEcCtD
Zuclopenthixol—Syncope—Ramipril—type 2 diabetes mellitus	7.88e-05	0.000452	CcSEcCtD
Zuclopenthixol—Leukopenia—Ramipril—type 2 diabetes mellitus	7.86e-05	0.000451	CcSEcCtD
Zuclopenthixol—Headache—Glyburide—type 2 diabetes mellitus	7.85e-05	0.00045	CcSEcCtD
Zuclopenthixol—Dyspepsia—Irbesartan—type 2 diabetes mellitus	7.82e-05	0.000449	CcSEcCtD
Zuclopenthixol—Hypotension—Losartan—type 2 diabetes mellitus	7.81e-05	0.000448	CcSEcCtD
Zuclopenthixol—Palpitations—Ramipril—type 2 diabetes mellitus	7.76e-05	0.000445	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Metformin—type 2 diabetes mellitus	7.76e-05	0.000445	CcSEcCtD
Zuclopenthixol—Thiothixene—CYP1A2—type 2 diabetes mellitus	7.73e-05	0.0176	CrCbGaD
Zuclopenthixol—Pipotiazine—CYP1A2—type 2 diabetes mellitus	7.73e-05	0.0176	CrCbGaD
Zuclopenthixol—Decreased appetite—Irbesartan—type 2 diabetes mellitus	7.72e-05	0.000443	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Ramipril—type 2 diabetes mellitus	7.72e-05	0.000443	CcSEcCtD
Zuclopenthixol—Diarrhoea—Gliclazide—type 2 diabetes mellitus	7.7e-05	0.000442	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	7.7e-05	0.000442	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	7.67e-05	0.00044	CcSEcCtD
Zuclopenthixol—Fatigue—Irbesartan—type 2 diabetes mellitus	7.66e-05	0.00044	CcSEcCtD
Zuclopenthixol—Loxapine—ADRA2A—type 2 diabetes mellitus	7.64e-05	0.0174	CrCbGaD
Zuclopenthixol—Thioridazine—HTR2C—type 2 diabetes mellitus	7.63e-05	0.0174	CrCbGaD
Zuclopenthixol—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	7.62e-05	0.000437	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Valsartan—type 2 diabetes mellitus	7.62e-05	0.000437	CcSEcCtD
Zuclopenthixol—Convulsion—Ramipril—type 2 diabetes mellitus	7.61e-05	0.000437	CcSEcCtD
Zuclopenthixol—Perphenazine—ADRA2A—type 2 diabetes mellitus	7.61e-05	0.0174	CrCbGaD
Zuclopenthixol—Constipation—Irbesartan—type 2 diabetes mellitus	7.6e-05	0.000436	CcSEcCtD
Zuclopenthixol—Pain—Irbesartan—type 2 diabetes mellitus	7.6e-05	0.000436	CcSEcCtD
Zuclopenthixol—Insomnia—Losartan—type 2 diabetes mellitus	7.56e-05	0.000434	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Orlistat—type 2 diabetes mellitus	7.53e-05	0.000432	CcSEcCtD
Zuclopenthixol—Paraesthesia—Losartan—type 2 diabetes mellitus	7.51e-05	0.000431	CcSEcCtD
Zuclopenthixol—Myalgia—Ramipril—type 2 diabetes mellitus	7.48e-05	0.000429	CcSEcCtD
Zuclopenthixol—Quetiapine—ADRA2A—type 2 diabetes mellitus	7.46e-05	0.017	CrCbGaD
Zuclopenthixol—Dyspnoea—Losartan—type 2 diabetes mellitus	7.45e-05	0.000428	CcSEcCtD
Zuclopenthixol—Anxiety—Ramipril—type 2 diabetes mellitus	7.45e-05	0.000428	CcSEcCtD
Zuclopenthixol—Nausea—Glyburide—type 2 diabetes mellitus	7.44e-05	0.000427	CcSEcCtD
Zuclopenthixol—Abdominal pain—Metformin—type 2 diabetes mellitus	7.44e-05	0.000427	CcSEcCtD
Zuclopenthixol—Dizziness—Gliclazide—type 2 diabetes mellitus	7.44e-05	0.000427	CcSEcCtD
Zuclopenthixol—Somnolence—Losartan—type 2 diabetes mellitus	7.43e-05	0.000427	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	7.43e-05	0.000426	CcSEcCtD
Zuclopenthixol—Asthenia—Valsartan—type 2 diabetes mellitus	7.42e-05	0.000426	CcSEcCtD
Zuclopenthixol—Discomfort—Ramipril—type 2 diabetes mellitus	7.39e-05	0.000424	CcSEcCtD
Zuclopenthixol—Dyspepsia—Losartan—type 2 diabetes mellitus	7.36e-05	0.000422	CcSEcCtD
Zuclopenthixol—Asthenia—Orlistat—type 2 diabetes mellitus	7.33e-05	0.000421	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	7.32e-05	0.00042	CcSEcCtD
Zuclopenthixol—Pruritus—Valsartan—type 2 diabetes mellitus	7.31e-05	0.00042	CcSEcCtD
Zuclopenthixol—Dry mouth—Ramipril—type 2 diabetes mellitus	7.31e-05	0.00042	CcSEcCtD
Zuclopenthixol—Decreased appetite—Losartan—type 2 diabetes mellitus	7.27e-05	0.000417	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	7.27e-05	0.000417	CcSEcCtD
Zuclopenthixol—Pruritus—Orlistat—type 2 diabetes mellitus	7.23e-05	0.000415	CcSEcCtD
Zuclopenthixol—Fatigue—Losartan—type 2 diabetes mellitus	7.21e-05	0.000414	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	7.17e-05	0.000411	CcSEcCtD
Zuclopenthixol—Vomiting—Gliclazide—type 2 diabetes mellitus	7.15e-05	0.000411	CcSEcCtD
Zuclopenthixol—Constipation—Losartan—type 2 diabetes mellitus	7.15e-05	0.00041	CcSEcCtD
Zuclopenthixol—Pain—Losartan—type 2 diabetes mellitus	7.15e-05	0.00041	CcSEcCtD
Zuclopenthixol—Domperidone—CYP3A4—type 2 diabetes mellitus	7.11e-05	0.0162	CrCbGaD
Zuclopenthixol—Rash—Gliclazide—type 2 diabetes mellitus	7.1e-05	0.000407	CcSEcCtD
Zuclopenthixol—Dermatitis—Gliclazide—type 2 diabetes mellitus	7.09e-05	0.000407	CcSEcCtD
Zuclopenthixol—Trifluoperazine—HTR2C—type 2 diabetes mellitus	7.08e-05	0.0162	CrCbGaD
Zuclopenthixol—Diarrhoea—Valsartan—type 2 diabetes mellitus	7.07e-05	0.000406	CcSEcCtD
Zuclopenthixol—Shock—Ramipril—type 2 diabetes mellitus	7.05e-05	0.000405	CcSEcCtD
Zuclopenthixol—Headache—Gliclazide—type 2 diabetes mellitus	7.05e-05	0.000404	CcSEcCtD
Zuclopenthixol—Loxapine—HTR2C—type 2 diabetes mellitus	7.03e-05	0.0161	CrCbGaD
Zuclopenthixol—Nervous system disorder—Ramipril—type 2 diabetes mellitus	7.03e-05	0.000403	CcSEcCtD
Zuclopenthixol—Body temperature increased—Irbesartan—type 2 diabetes mellitus	7.02e-05	0.000403	CcSEcCtD
Zuclopenthixol—Abdominal pain—Irbesartan—type 2 diabetes mellitus	7.02e-05	0.000403	CcSEcCtD
Zuclopenthixol—Fluphenazine—CYP2E1—type 2 diabetes mellitus	7.02e-05	0.016	CrCbGaD
Zuclopenthixol—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	7.02e-05	0.000403	CcSEcCtD
Zuclopenthixol—Perphenazine—HTR2C—type 2 diabetes mellitus	7e-05	0.016	CrCbGaD
Zuclopenthixol—Tachycardia—Ramipril—type 2 diabetes mellitus	7e-05	0.000401	CcSEcCtD
Zuclopenthixol—Diarrhoea—Orlistat—type 2 diabetes mellitus	6.99e-05	0.000401	CcSEcCtD
Zuclopenthixol—Skin disorder—Ramipril—type 2 diabetes mellitus	6.96e-05	0.0004	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	6.93e-05	0.000398	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Losartan—type 2 diabetes mellitus	6.89e-05	0.000395	CcSEcCtD
Zuclopenthixol—Quetiapine—HTR2C—type 2 diabetes mellitus	6.87e-05	0.0157	CrCbGaD
Zuclopenthixol—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	6.84e-05	0.000392	CcSEcCtD
Zuclopenthixol—Dizziness—Valsartan—type 2 diabetes mellitus	6.84e-05	0.000392	CcSEcCtD
Zuclopenthixol—Anorexia—Ramipril—type 2 diabetes mellitus	6.83e-05	0.000392	CcSEcCtD
Zuclopenthixol—Dizziness—Orlistat—type 2 diabetes mellitus	6.76e-05	0.000388	CcSEcCtD
Zuclopenthixol—Asthenia—Metformin—type 2 diabetes mellitus	6.76e-05	0.000388	CcSEcCtD
Zuclopenthixol—Hypotension—Ramipril—type 2 diabetes mellitus	6.7e-05	0.000384	CcSEcCtD
Zuclopenthixol—Nausea—Gliclazide—type 2 diabetes mellitus	6.68e-05	0.000384	CcSEcCtD
Zuclopenthixol—Fluphenazine—CYP1A2—type 2 diabetes mellitus	6.68e-05	0.0153	CrCbGaD
Zuclopenthixol—Pruritus—Metformin—type 2 diabetes mellitus	6.66e-05	0.000382	CcSEcCtD
Zuclopenthixol—Body temperature increased—Losartan—type 2 diabetes mellitus	6.61e-05	0.000379	CcSEcCtD
Zuclopenthixol—Abdominal pain—Losartan—type 2 diabetes mellitus	6.61e-05	0.000379	CcSEcCtD
Zuclopenthixol—Vomiting—Valsartan—type 2 diabetes mellitus	6.57e-05	0.000377	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	6.55e-05	0.000376	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	6.53e-05	0.000375	CcSEcCtD
Zuclopenthixol—Rash—Valsartan—type 2 diabetes mellitus	6.52e-05	0.000374	CcSEcCtD
Zuclopenthixol—Dermatitis—Valsartan—type 2 diabetes mellitus	6.51e-05	0.000374	CcSEcCtD
Zuclopenthixol—Vomiting—Orlistat—type 2 diabetes mellitus	6.5e-05	0.000373	CcSEcCtD
Zuclopenthixol—Insomnia—Ramipril—type 2 diabetes mellitus	6.48e-05	0.000372	CcSEcCtD
Zuclopenthixol—Headache—Valsartan—type 2 diabetes mellitus	6.48e-05	0.000372	CcSEcCtD
Zuclopenthixol—Diarrhoea—Metformin—type 2 diabetes mellitus	6.44e-05	0.00037	CcSEcCtD
Zuclopenthixol—Rash—Orlistat—type 2 diabetes mellitus	6.44e-05	0.00037	CcSEcCtD
Zuclopenthixol—Paraesthesia—Ramipril—type 2 diabetes mellitus	6.44e-05	0.000369	CcSEcCtD
Zuclopenthixol—Dermatitis—Orlistat—type 2 diabetes mellitus	6.44e-05	0.000369	CcSEcCtD
Zuclopenthixol—Clozapine—ADRA2A—type 2 diabetes mellitus	6.42e-05	0.0146	CrCbGaD
Zuclopenthixol—Headache—Orlistat—type 2 diabetes mellitus	6.4e-05	0.000367	CcSEcCtD
Zuclopenthixol—Dyspnoea—Ramipril—type 2 diabetes mellitus	6.39e-05	0.000367	CcSEcCtD
Zuclopenthixol—Asthenia—Irbesartan—type 2 diabetes mellitus	6.37e-05	0.000366	CcSEcCtD
Zuclopenthixol—Somnolence—Ramipril—type 2 diabetes mellitus	6.37e-05	0.000366	CcSEcCtD
Zuclopenthixol—Dyspepsia—Ramipril—type 2 diabetes mellitus	6.31e-05	0.000362	CcSEcCtD
Zuclopenthixol—Pruritus—Irbesartan—type 2 diabetes mellitus	6.29e-05	0.000361	CcSEcCtD
Zuclopenthixol—Decreased appetite—Ramipril—type 2 diabetes mellitus	6.23e-05	0.000358	CcSEcCtD
Zuclopenthixol—Dizziness—Metformin—type 2 diabetes mellitus	6.23e-05	0.000357	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	6.19e-05	0.000355	CcSEcCtD
Zuclopenthixol—Fatigue—Ramipril—type 2 diabetes mellitus	6.18e-05	0.000355	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Losartan—type 2 diabetes mellitus	6.16e-05	0.000353	CcSEcCtD
Zuclopenthixol—Nausea—Valsartan—type 2 diabetes mellitus	6.14e-05	0.000352	CcSEcCtD
Zuclopenthixol—Constipation—Ramipril—type 2 diabetes mellitus	6.13e-05	0.000352	CcSEcCtD
Zuclopenthixol—Diarrhoea—Irbesartan—type 2 diabetes mellitus	6.08e-05	0.000349	CcSEcCtD
Zuclopenthixol—Nausea—Orlistat—type 2 diabetes mellitus	6.07e-05	0.000348	CcSEcCtD
Zuclopenthixol—Thioridazine—CYP2E1—type 2 diabetes mellitus	6.05e-05	0.0138	CrCbGaD
Zuclopenthixol—Chlorpromazine—ADRA2A—type 2 diabetes mellitus	6.03e-05	0.0138	CrCbGaD
Zuclopenthixol—Asthenia—Losartan—type 2 diabetes mellitus	6e-05	0.000344	CcSEcCtD
Zuclopenthixol—Vomiting—Metformin—type 2 diabetes mellitus	5.99e-05	0.000343	CcSEcCtD
Zuclopenthixol—Rash—Metformin—type 2 diabetes mellitus	5.94e-05	0.000341	CcSEcCtD
Zuclopenthixol—Dermatitis—Metformin—type 2 diabetes mellitus	5.93e-05	0.00034	CcSEcCtD
Zuclopenthixol—Pruritus—Losartan—type 2 diabetes mellitus	5.92e-05	0.000339	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Ramipril—type 2 diabetes mellitus	5.91e-05	0.000339	CcSEcCtD
Zuclopenthixol—Clozapine—HTR2C—type 2 diabetes mellitus	5.91e-05	0.0135	CrCbGaD
Zuclopenthixol—Nefazodone—CYP3A4—type 2 diabetes mellitus	5.9e-05	0.0135	CrCbGaD
Zuclopenthixol—Headache—Metformin—type 2 diabetes mellitus	5.9e-05	0.000338	CcSEcCtD
Zuclopenthixol—Dizziness—Irbesartan—type 2 diabetes mellitus	5.88e-05	0.000337	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	5.86e-05	0.000336	CcSEcCtD
Zuclopenthixol—Thioridazine—CYP1A2—type 2 diabetes mellitus	5.76e-05	0.0131	CrCbGaD
Zuclopenthixol—Diarrhoea—Losartan—type 2 diabetes mellitus	5.72e-05	0.000328	CcSEcCtD
Zuclopenthixol—Abdominal pain—Ramipril—type 2 diabetes mellitus	5.67e-05	0.000325	CcSEcCtD
Zuclopenthixol—Body temperature increased—Ramipril—type 2 diabetes mellitus	5.67e-05	0.000325	CcSEcCtD
Zuclopenthixol—Vomiting—Irbesartan—type 2 diabetes mellitus	5.65e-05	0.000324	CcSEcCtD
Zuclopenthixol—Rash—Irbesartan—type 2 diabetes mellitus	5.6e-05	0.000321	CcSEcCtD
Zuclopenthixol—Dermatitis—Irbesartan—type 2 diabetes mellitus	5.6e-05	0.000321	CcSEcCtD
Zuclopenthixol—Nausea—Metformin—type 2 diabetes mellitus	5.59e-05	0.000321	CcSEcCtD
Zuclopenthixol—Headache—Irbesartan—type 2 diabetes mellitus	5.57e-05	0.000319	CcSEcCtD
Zuclopenthixol—Chlorpromazine—HTR2C—type 2 diabetes mellitus	5.55e-05	0.0127	CrCbGaD
Zuclopenthixol—Dizziness—Losartan—type 2 diabetes mellitus	5.53e-05	0.000317	CcSEcCtD
Zuclopenthixol—Trazodone—CYP3A4—type 2 diabetes mellitus	5.46e-05	0.0125	CrCbGaD
Zuclopenthixol—Trifluoperazine—CYP1A2—type 2 diabetes mellitus	5.34e-05	0.0122	CrCbGaD
Zuclopenthixol—Vomiting—Losartan—type 2 diabetes mellitus	5.32e-05	0.000305	CcSEcCtD
Zuclopenthixol—Perphenazine—CYP1A2—type 2 diabetes mellitus	5.28e-05	0.0121	CrCbGaD
Zuclopenthixol—Hypersensitivity—Ramipril—type 2 diabetes mellitus	5.28e-05	0.000303	CcSEcCtD
Zuclopenthixol—Nausea—Irbesartan—type 2 diabetes mellitus	5.28e-05	0.000303	CcSEcCtD
Zuclopenthixol—Rash—Losartan—type 2 diabetes mellitus	5.27e-05	0.000302	CcSEcCtD
Zuclopenthixol—Dermatitis—Losartan—type 2 diabetes mellitus	5.27e-05	0.000302	CcSEcCtD
Zuclopenthixol—Headache—Losartan—type 2 diabetes mellitus	5.24e-05	0.000301	CcSEcCtD
Zuclopenthixol—Asthenia—Ramipril—type 2 diabetes mellitus	5.14e-05	0.000295	CcSEcCtD
Zuclopenthixol—Pipotiazine—CYP3A4—type 2 diabetes mellitus	5.12e-05	0.0117	CrCbGaD
Zuclopenthixol—Pruritus—Ramipril—type 2 diabetes mellitus	5.07e-05	0.000291	CcSEcCtD
Zuclopenthixol—Nausea—Losartan—type 2 diabetes mellitus	4.97e-05	0.000285	CcSEcCtD
Zuclopenthixol—Diarrhoea—Ramipril—type 2 diabetes mellitus	4.91e-05	0.000281	CcSEcCtD
Zuclopenthixol—Prochlorperazine—CYP3A4—type 2 diabetes mellitus	4.89e-05	0.0112	CrCbGaD
Zuclopenthixol—Dizziness—Ramipril—type 2 diabetes mellitus	4.74e-05	0.000272	CcSEcCtD
Zuclopenthixol—Clozapine—CYP2E1—type 2 diabetes mellitus	4.68e-05	0.0107	CrCbGaD
Zuclopenthixol—Vomiting—Ramipril—type 2 diabetes mellitus	4.56e-05	0.000262	CcSEcCtD
Zuclopenthixol—Thioproperazine—ALB—type 2 diabetes mellitus	4.54e-05	0.0104	CrCbGaD
Zuclopenthixol—Rash—Ramipril—type 2 diabetes mellitus	4.52e-05	0.000259	CcSEcCtD
Zuclopenthixol—Dermatitis—Ramipril—type 2 diabetes mellitus	4.52e-05	0.000259	CcSEcCtD
Zuclopenthixol—Headache—Ramipril—type 2 diabetes mellitus	4.49e-05	0.000258	CcSEcCtD
Zuclopenthixol—Pipotiazine—ALB—type 2 diabetes mellitus	4.46e-05	0.0102	CrCbGaD
Zuclopenthixol—Thiothixene—ALB—type 2 diabetes mellitus	4.46e-05	0.0102	CrCbGaD
Zuclopenthixol—Clozapine—CYP1A2—type 2 diabetes mellitus	4.46e-05	0.0102	CrCbGaD
Zuclopenthixol—Chlorpromazine—CYP2E1—type 2 diabetes mellitus	4.41e-05	0.0101	CrCbGaD
Zuclopenthixol—Nausea—Ramipril—type 2 diabetes mellitus	4.26e-05	0.000244	CcSEcCtD
Zuclopenthixol—Chlorpromazine—CYP1A2—type 2 diabetes mellitus	4.19e-05	0.00957	CrCbGaD
Zuclopenthixol—Perphenazine—CYP3A4—type 2 diabetes mellitus	3.5e-05	0.00798	CrCbGaD
Zuclopenthixol—Quetiapine—CYP3A4—type 2 diabetes mellitus	3.43e-05	0.00783	CrCbGaD
Zuclopenthixol—Clozapine—CYP3A4—type 2 diabetes mellitus	2.95e-05	0.00673	CrCbGaD
Zuclopenthixol—Chlorpromazine—CYP3A4—type 2 diabetes mellitus	2.77e-05	0.00633	CrCbGaD
Zuclopenthixol—Chlorpromazine—ALB—type 2 diabetes mellitus	2.42e-05	0.00553	CrCbGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	4.95e-06	6.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	4.95e-06	6.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	4.93e-06	6.02e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.93e-06	6.02e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	4.9e-06	5.98e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	4.9e-06	5.98e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—SRC—type 2 diabetes mellitus	4.89e-06	5.97e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.87e-06	5.95e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	4.87e-06	5.95e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.86e-06	5.94e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.86e-06	5.94e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.84e-06	5.92e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.84e-06	5.91e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AGT—type 2 diabetes mellitus	4.84e-06	5.91e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.82e-06	5.89e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—RELA—type 2 diabetes mellitus	4.8e-06	5.87e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.79e-06	5.85e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.78e-06	5.83e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	4.77e-06	5.83e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.77e-06	5.83e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.76e-06	5.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—CALM1—type 2 diabetes mellitus	4.75e-06	5.81e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—C3—type 2 diabetes mellitus	4.75e-06	5.81e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—APOE—type 2 diabetes mellitus	4.74e-06	5.79e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	4.73e-06	5.77e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	4.69e-06	5.73e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	4.69e-06	5.73e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.69e-06	5.72e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—APOA1—type 2 diabetes mellitus	4.68e-06	5.72e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—C3—type 2 diabetes mellitus	4.68e-06	5.71e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—C3—type 2 diabetes mellitus	4.67e-06	5.7e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.63e-06	5.65e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.6e-06	5.62e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—C3—type 2 diabetes mellitus	4.58e-06	5.59e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.53e-06	5.54e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.52e-06	5.52e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AGT—type 2 diabetes mellitus	4.52e-06	5.52e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.46e-06	5.45e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.45e-06	5.44e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.45e-06	5.44e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AGT—type 2 diabetes mellitus	4.44e-06	5.43e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.44e-06	5.42e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.44e-06	5.42e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AGT—type 2 diabetes mellitus	4.43e-06	5.42e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.43e-06	5.42e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—LEP—type 2 diabetes mellitus	4.43e-06	5.41e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—APOE—type 2 diabetes mellitus	4.43e-06	5.41e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.39e-06	5.36e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.39e-06	5.36e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.37e-06	5.34e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.37e-06	5.34e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.37e-06	5.34e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.37e-06	5.34e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.37e-06	5.33e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.36e-06	5.33e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.36e-06	5.32e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.35e-06	5.32e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—LEP—type 2 diabetes mellitus	4.35e-06	5.32e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—APOE—type 2 diabetes mellitus	4.35e-06	5.32e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AGT—type 2 diabetes mellitus	4.35e-06	5.32e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—APOE—type 2 diabetes mellitus	4.35e-06	5.31e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—LEP—type 2 diabetes mellitus	4.35e-06	5.31e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.33e-06	5.29e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.3e-06	5.26e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.3e-06	5.26e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.3e-06	5.25e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.29e-06	5.23e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.28e-06	5.23e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—LEP—type 2 diabetes mellitus	4.26e-06	5.21e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—APOE—type 2 diabetes mellitus	4.26e-06	5.21e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	4.26e-06	5.2e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.22e-06	5.15e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.17e-06	5.1e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—RELA—type 2 diabetes mellitus	4.13e-06	5.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	4.13e-06	5.04e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.11e-06	5.02e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.1e-06	5.01e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.09e-06	5e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.06e-06	4.96e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.05e-06	4.95e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.05e-06	4.94e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	4.05e-06	4.94e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	4.05e-06	4.94e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.05e-06	4.94e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	4.04e-06	4.94e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	4.03e-06	4.92e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	4.02e-06	4.92e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.02e-06	4.91e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.98e-06	4.86e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	3.97e-06	4.85e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.97e-06	4.85e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	3.96e-06	4.84e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	3.96e-06	4.84e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.95e-06	4.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.92e-06	4.78e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.88e-06	4.74e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.88e-06	4.73e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	3.86e-06	4.71e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.8e-06	4.65e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—INS—type 2 diabetes mellitus	3.78e-06	4.62e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—SRC—type 2 diabetes mellitus	3.77e-06	4.61e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.76e-06	4.6e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	3.75e-06	4.58e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.74e-06	4.56e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.73e-06	4.55e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—INS—type 2 diabetes mellitus	3.72e-06	4.54e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.72e-06	4.54e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—INS—type 2 diabetes mellitus	3.71e-06	4.53e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	3.71e-06	4.53e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.7e-06	4.52e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	3.68e-06	4.5e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.68e-06	4.49e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.66e-06	4.47e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.66e-06	4.47e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.65e-06	4.46e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.65e-06	4.46e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—INS—type 2 diabetes mellitus	3.64e-06	4.45e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.64e-06	4.44e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	3.61e-06	4.4e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.6e-06	4.4e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.6e-06	4.39e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	3.59e-06	4.39e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.59e-06	4.39e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.59e-06	4.38e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.58e-06	4.38e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.58e-06	4.37e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.57e-06	4.36e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	3.55e-06	4.34e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	3.55e-06	4.34e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.53e-06	4.32e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.52e-06	4.3e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.52e-06	4.3e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.52e-06	4.3e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.51e-06	4.28e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	3.5e-06	4.27e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.49e-06	4.26e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.47e-06	4.24e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	3.46e-06	4.22e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.42e-06	4.17e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.42e-06	4.17e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.41e-06	4.16e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	3.38e-06	4.13e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.37e-06	4.12e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.35e-06	4.09e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.33e-06	4.07e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	3.32e-06	4.05e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.32e-06	4.05e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.32e-06	4.05e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.31e-06	4.04e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IL6—type 2 diabetes mellitus	3.29e-06	4.02e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.27e-06	4e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.27e-06	4e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.26e-06	3.98e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.26e-06	3.98e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.26e-06	3.98e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.26e-06	3.98e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.26e-06	3.98e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	3.25e-06	3.97e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—SRC—type 2 diabetes mellitus	3.25e-06	3.97e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	3.25e-06	3.97e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.19e-06	3.9e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.19e-06	3.9e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.16e-06	3.86e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	3.15e-06	3.85e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—RELA—type 2 diabetes mellitus	3.12e-06	3.81e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.11e-06	3.8e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	3.1e-06	3.78e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	3.09e-06	3.77e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	3.07e-06	3.75e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—RELA—type 2 diabetes mellitus	3.06e-06	3.74e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	3.05e-06	3.73e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.04e-06	3.71e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	3.01e-06	3.67e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.97e-06	3.63e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.97e-06	3.63e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.9e-06	3.55e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.85e-06	3.48e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.84e-06	3.47e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.81e-06	3.44e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.8e-06	3.42e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.8e-06	3.41e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	2.79e-06	3.41e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.79e-06	3.41e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.77e-06	3.38e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.76e-06	3.38e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.75e-06	3.36e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.75e-06	3.35e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.74e-06	3.34e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.71e-06	3.31e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.69e-06	3.29e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	2.69e-06	3.28e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.66e-06	3.25e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	2.64e-06	3.22e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.63e-06	3.21e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.62e-06	3.2e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.61e-06	3.19e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.59e-06	3.16e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.58e-06	3.16e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.58e-06	3.15e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.56e-06	3.13e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.54e-06	3.11e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IL6—type 2 diabetes mellitus	2.54e-06	3.1e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.54e-06	3.1e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.54e-06	3.1e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.53e-06	3.09e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.52e-06	3.08e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.5e-06	3.06e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.49e-06	3.04e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SRC—type 2 diabetes mellitus	2.45e-06	3e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	2.42e-06	2.95e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	2.41e-06	2.95e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.41e-06	2.94e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.39e-06	2.92e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.38e-06	2.91e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	2.36e-06	2.89e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.36e-06	2.88e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.35e-06	2.87e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.35e-06	2.86e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.35e-06	2.86e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	2.31e-06	2.83e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	2.31e-06	2.83e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.31e-06	2.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.3e-06	2.81e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	2.2e-06	2.68e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.19e-06	2.68e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IL6—type 2 diabetes mellitus	2.19e-06	2.67e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.16e-06	2.63e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.15e-06	2.63e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.15e-06	2.63e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.14e-06	2.61e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	2.12e-06	2.58e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.12e-06	2.58e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.11e-06	2.58e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.11e-06	2.58e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.07e-06	2.53e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.02e-06	2.47e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.96e-06	2.4e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.92e-06	2.35e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.65e-06	2.02e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	1.63e-06	1.99e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.63e-06	1.99e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.62e-06	1.98e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.59e-06	1.94e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.52e-06	1.86e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.5e-06	1.83e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.5e-06	1.83e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.48e-06	1.81e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.47e-06	1.79e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.36e-06	1.67e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	1.06e-06	1.3e-05	CbGpPWpGaD
